Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda Gray, James G. Kublin, Barbara Metch et al.|The Lancet Infectious Diseases|2011Cited by 385
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Hua-Xin Liao et al.|Science|2015Cited by 202
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams et al.|PLoS ONE|2011Cited by 137
Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or ImmunizationCheng Cheng, Gary J. Nabel, Jason G. Gall et al.|Journal of Virology|2009Cited by 75